These are promising findings adding to a growing body of evidence showing that virtual reality can be used to measure cognition and related everyday functioning effectively and accurately. The next steps will be to confirm these results and expand research into conditions characterised by cognitive complaints and functional difficulties such as psychosis and Alzheimer’s Disease.
Alzheimer’s disease is the most common and best known of the tauopathies, a set of neurodegenerative brain diseases caused by toxic tangles of the protein tau. A study by researchers at Washington University School of Medicine in St. Louis has shown that targeting astrocytes — an inflammatory cell in the brain — reduces tau-related brain damage and inflammation in mice.
Now a couple of years after this discovery, Pete Nelson, the R.C. Durr Foundation Chair in Alzheimer's Disease at the University of Kentucky, is working towards the second part of the dream, with the world’s first clinical trial for LATE officially underway by his colleagues at UK.
Daytime napping is common among older adults. The longitudinal relationship between daytime napping and cognitive aging, however, is unknown.
Mayo Clinic researchers have identified a new set of molecular markers in blood plasma. This discovery could lead to the development of improved diagnostic tests for Alzheimer's disease. Alzheimer's disease is the most common form of dementia, affecting 6.2 million people in the U.S. The Mayo Clinic study, published in eBioMedicine, is the first study to focus on RNA molecules in plasma as biomarkers for Alzheimer's disease in African Americans — the population at greatest risk for developing Alzheimer's disease. This approach enabled researchers to pinpoint specific molecules in plasma that could serve as biomarkers to confirm a diagnosis of Alzheimer's disease in this population.
The Dementia Care Study (D-CARE), a nation-wide clinical trial assessing the effectiveness of different approaches to caring for people with Alzheimer’s disease and other dementias, has reached its recruitment goal by enrolling 2,176 persons living with dementia and their caregivers
Mayo Clinic researchers say senolytic drugs can boost a key protein in the body that protects older people against aspects of aging and a range of diseases. Their findings, which are published in eBioMedicine demonstrate this in mice and human studies. Senolytics developed at Mayo Clinic and given once clear the bloodstream of senescent or "zombie" cells. These cells contribute to multiple diseases and negative aspects of aging. This study shows that the removal of senescent cells significantly boosts the production of a protective protein called a-klotho.
Cognitive decline is the biggest factor in determining how long patients with Alzheimer’s disease will live after being diagnosed, according to a new study from researchers at UT Southwestern. The findings, published in the Journal of Alzheimer’s Disease, are a first step that could help health care providers provide reliable prediction and planning assistance for patients with Alzheimer’s disease and their families.
People living with neurological or psychiatric conditions may have an increased likelihood of having a second such condition in the future, and their sex influences their risk, according to new research.
The 147th Annual Meeting of the American Neurological Association (taking place in-person October 22–25, 2022 in Chicago) will explore new frontiers in neurology, including climate change and the brain, lab-grown brain structures for studying disease, and addressing disparities in neurologic care.
New Neuroscience Institute to Focus Research on Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's Disease, and will treat patients with other neurological conditions, including epilepsy, seizures and Alzheimer’s Disease
A Johns Hopkins Medicine study of about 50 people with Alzheimer’s disease has added to evidence that damage to the inner ear system that controls balance is a major factor in patients’ well-documented higher risk of falling.
The University of Kentucky’s Sanders-Brown Center on Aging has been around for nearly half a century. In that time, they have built an international reputation for best-in-class research into a disease that kills more people every year than breast and prostate cancer combined – Alzheimer’s disease. There are several components to the ongoing research at Sanders-Brown, one is exploring ways to detect Alzheimer’s earlier in a person’s life.
Researchers have received grants from the Florida Department of Health’s Ed and Ethel Moore Foundation for Alzheimer’s Disease Research, for programs focused on the mechanism of genes involved in neurodegeneration using novel genetic models, and to develop a culturally relevant model to diagnose and manage dementia in rural underserved communities.
Don't miss these articles in our Staff Picks channel
As scientists around the world seek for solutions for Alzheimer’s disease, a new study reveals that two indigenous groups in the Bolivian Amazon have among the lowest rates of dementia in the world.
Researchers have discovered two types of brain cells that play a key role in dividing continuous human experience into distinct segments that can be recalled later. The discovery provides new promise as a path toward development of novel treatments for memory disorders such as dementia and Alzheimer’s disease.
People who are more physically fit are less likely to develop Alzheimer’s disease than people who are less physically fit, according to a preliminary study released today, February 27, 2022, that will be presented at the American Academy of Neurology’s 74th Annual Meeting being held in person in Seattle, April 2 to 7, 2022 and virtually, April 24 to 26, 2022.
Now that the holiday season has concluded, perhaps you’ve noticed the warning signs of Alzheimer’s disease or related dementia in aging family members. George Grossberg, M.D., the Samuel W. Fordyce professor and director of geriatric psychiatry at Saint Louis University School of Medicine, said it is during family gatherings that caregivers often notice older adults 65 and over may be slipping cognitively.
Among people with no memory or thinking problems, having a poor score on a simple memory test may be linked to biomarkers in the brain associated with Alzheimer’s disease as well as very early signs of memory impairment that precede dementia by several years, according to a study published in the February 23, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology.
To help neurologists, patients and their families understand the current evidence on the use of aducanumab to treat Alzheimer’s disease, the American Academy of Neurology (AAN) has issued an evidence-in-focus article, published in the February 23, 2022, online issue of Neurology®, the medical journal of the AAN. The article also includes a discussion of the safety, costs, administration, and quality-of-life issues related to aducanumab to provide people with a more detailed understanding of the new treatment.
A pioneering new study led by UCL and National Institutes of Health (NIH) scientists has revealed, for the first time, why a common genetic variant worsens disease outcomes for people with the devastating adult-onset neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
A blood test developed at Washington University School of Medicine in St. Louis has proven highly accurate in detecting early signs of Alzheimer’s disease in a study involving nearly 500 patients from across three continents, providing further evidence that the test should be considered for routine screening and diagnosis. The study is available in the journal Neurology.
A new imaging technology from the lab of Matthew Lew at the McKelvey School of Engineering uses polarized “optical vortices” to provide a detailed, dynamic view of molecules in motion.
UT Southwestern Medical Center has completed a five-year, $1 billion campaign to fuel its commitment to advance brain research and clinical care at its Peter O’Donnell Jr. Brain Institute, making it one of the largest brain-focused investments at a U.S. academic medical center.
Irvine, Calif., Feb. 15, 2022 – In a scientific first, researchers at the University of California, Irvine have discovered fundamental mechanisms by which the hippocampus region of the brain organizes memories into sequences and how this can be used to plan future behavior. The finding may be a critical early step toward understanding memory failures in cognitive disorders such as Alzheimer’s disease and other forms of dementia.
The brain’s ability to clear a protein closely linked to Alzheimer’s disease is tied to our circadian cycle, according to research published in PLOS Genetics.
Studies have shown that Aboriginal Australians living in remote areas of the country are disproportionately affected by dementia, with rates approximately double those of non-Indigenous people. A new study shows that Aboriginal Australians living in urban areas also have similar high rates of dementia. The study is published in the February 9, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study looked at Aboriginal Australians and Torres Strait Islander peoples
Having two or more chronic conditions (known as multimorbidity) in middle age is associated with an increased risk of dementia later in life, finds a large study of British adults, published by The BMJ today.
Scientists have successfully tested in the lab a tiny biosensor they developed that can detect biomarkers tied to traumatic brain injuries.
Cleveland Clinic and Maria Shriver, founder of The Women’s Alzheimer’s Movement (WAM), announced a ground-breaking partnership today aimed at further addressing and reducing women’s risk for Alzheimer’s disease: The Women’s Alzheimer’s Movement at Cleveland Clinic (WAM at Cleveland Clinic).
Alzheimer's and other dementias are among the most widespread diseases today. Diagnosis is complex and can often only be established with certainty late in the course of the disease. A team of Empa researchers, together with clinical partners, is now developing a new diagnostic tool that can detect the first signs of neurodegenerative changes using a sensor belt.
Cognitive changes following non-neurologic and non-cardiac surgery were not associated with changes in Alzheimer’s disease-related biomarkers in older patients, according to a study led by a team at Duke University School of Medicine.
A team of researchers from the University of Kentucky’s Sanders-Brown Center on Aging is working to identify new proteins that are destructive to the brain. They know that about 25% of individuals, and 50% of individuals with Alzheimer disease, have the genetic mutation APOE ε4 allele — a known risk factor for the disease. Through a recent study, researchers were surprised to find that even in the brains of patients without the disease-driving mutation, ApoE proteins were enhanced in dementia. Their findings appear in The American Journal of Pathology, published by Elsevier.
A new study has found that greater body fat is a risk factor for reduced cognitive function, such as processing speed, in adults. Even when the researchers took cardiovascular risk factors (such as diabetes or high blood pressure) or vascular brain injury into account, the association between body fat and lower cognitive scores remained. This suggests other not yet confirmed pathways that linked excess body fat to reduced cognitive function.
Researchers from Radboudumc have developed a set of growth charts for the brain.
Sanford Burnham Prebys professor Yu Yamaguchi has been awarded a $2.9 million grant from the National Institutes of Health to study the role of heparan sulfate (HS) in Alzheimer’s disease. HS is a structural molecule found in the scaffolding between cells that has been previously observed to influence the development of Alzheimer’s disease. However, the precise function it plays in the brain has not been studied closely.
University of Maryland School of Medicine researchers developed a technique in laboratory animals to consistently and reproducibly open the blood-brain barrier. Their paper essentially provides a roadmap for other researchers to develop and test new therapies for brain diseases.
Ten years ago, on Jan. 23, 2012, the brand-new University of Kansas Clinical Research Center opened its doors.
A cost analysis of the controversial new Alzheimer’s disease drug aducanumab shows that ancillary care services account for nearly 20% of total Medicare costs related to the drug, or $6,564 per patient per year.
The latest research news from the Health Disparities Channel.
Researchers from the Icahn School of Medicine at Mount Sinai have found that greater increases, decreases, or variability in body mass index (BMI) over time are associated with an accelerated rate of cognitive decline, irrespective of whether a person has normal, overweight or obese body mass index at baseline.
Researchers have determined the optimal number of intervention sessions needed to prevent cognitive decline in people at risk.
CLEVELAND: Cleveland Clinic has launched a landmark study to better understand why millions of people around the world suffer from brain diseases, with the goal of pinpointing disease biomarkers early, well before clinical symptoms present themselves. The new Cleveland Clinic Brain Study – the largest clinical study ever for brain disease – will collect data from up to 200,000 neurologically healthy individuals over a 20-year period to identify brain disease biomarkers and targets for preventing and curing neurological disorders.
Scientists have discovered that heart disease causes brain dysfunction that could lead to dementia before the buildup of plaque in blood vessels of the brain
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
